Personalized Cancer Testing
- Early Detection of Cancer
- Evaluation of tumour progression in real-time.
- Identification of patients who are likely to respond to treatment of curative intent – Personalised Treatements
- Prediction of long-term prognosis
- Assessment of likelihood of recurrence (MRD).
Immune Frame Test
Profile of humoral and cellular immunity and cachexia. This test uses specific cellular markers and cytokine production to detect the type/types of cells that are responsible for activation / repression of the immune system of host.See more >
Metastat RGCC Test
Markers on CTCs that point out the potential organ for relapse. It can help practitioners in the prognosis of metastases trends in cancer patients and guide them in the choice of appropriate chemotherapy.See more >
Oncotrail RGCC Test
This test is a tailor made test for a specific type of malignancy such as breast cancer (Oncotrail for Breast), prostate (Oncotrail for Prostate), Colon, Melanoma, Lung, Sarcoma, Gastrointestinal for follow up control.See more >
Oncotrace RGCC Test
This test will report the number of CTC's, any positive CSC's, and the immunophenotype of these cells.See more >
Onconomics Plus RGCC Test
This test includes the assessment of cytotoxic drugs, natural substances and plant extracts for any anticancer potency. The complete information for personal cancer care and support.See more >
Onconomics Extracts Test
This test includes only the assessment of natural substances and plant extracts for any anticancer potency. No chemotherapeutic agents tested and no tumor suppressor genes tested.See more >
Onconomics RGCC Test
This test includes the chemosensitivity / chemoresistance assessment for cytotoxic drugs, monoclonal antibodies, and small molecules that inhibit specific targets eg. (TKI, etc.). No natural substances tested.See more >
Oncocount RGCC Test
This test will report only the number of Circulating Cancer Tumor Cells (CTC's). It does not include any other information concerning the CTC's or Circulating Cancer Stem Cells (CSC's) Immunophenotyping.See more >
It is well established by literature and validation that the overall response rate from empirical chemotherapy varies from 5 to 7.5% (Royal North Shore Hospital ClinOncol (R Coll Radiol) 2005 Jun;17(4):294). Pharmaceutical industry assesses and validates candidate drugs by utilizing extensive chemosensitivity assays under the term of High Throughput Screening (HTS). Cancer is caused by severe damaged genetic material which leads to random genetic instability. So, each malignancy behaves differently to each individual. Each person has different genetic fingerprinting from others.
The tumor is consisted of several subgroups of cells (subpopulations) with different features. One of the subset actually drives the progress of the disease, the resistance to therapy and the relapse. This subset is called cancer stem cell like cells ortumor initiating cells. When a patient is treated and the cancer cells may be destroyed, then when the compatible diagnostic does not discover any signal, the cancer cells may consist a population of 10^9 to 10^12 cells. This limit defines the remission stage of a patient. At that stage only the cancer stem cells may survive and colonize into distant organs and generate metastases in time. Hence the usage of our test is to detect in which therapeutic approach the cancer cell may respond and also during remission, it is essential to detect, discover and explore the features of the disseminated cancer stem cell like, in order to delay further the risk of relapse and also to generate options to treat even these kinds of cells. The main goal is to discover, analyze and screen the cancer cells in every step of the disease.